Stifel Nicolaus Reiterates a Buy Rating on Lexicon Pharmaceuticals

By Jason Carr

In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), with a price target of $23. The company’s shares closed yesterday at $11.43.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.5% and a 50.9% success rate. Willey covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.

Currently, the analyst consensus on Lexicon Pharmaceuticals is a Moderate Buy with an average price target of $42.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.03 and a one-year low of $7.67. Currently, Lexicon Pharmaceuticals has an average volume of 666.6K.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LXRX in relation to earlier this year. Last month, James Tessmer, the VP, Finance & Accounting of LXRX sold 10,000 shares for a total of $129,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It also offers programs in clinical development for diabetes, irritable bowel syndrome, and carcinoid syndrome.